Russian Journal of BiotherapyRussian Journal of BiotherapyРоссийский биотерапевтический журнал1726-97841726-9792Publishing House ABV Press86010.17650/1726-9784-2017-16-2-6-12REVIEWSОБЗОРЫ ЛИТЕРАТУРЫIs there an association between prostate cancer and human papillomaviruses?Ассоциирован ли рак предстательной железы с вирусами папилломы человека?VolgarevaG. M.ВолгареваГ. М.
Russian Federation
galina.volgareva@ronc.ruN.N. Blokhin Russian Cancer Research Center, Ministry of Health of RussiaФГБУ«РОНЦ им. Н.Н. Блохина» Минздрава России3006201716261210042018https://bioterapevt.abvpress.ru/jour/article/view/860

Prostate cancer (PC) incidence and mortality are growing steadily the world over including Russia. PC incidence in 2014 made up 14.3 % of all male tumors in the Russian Federation. PC mortality growth rate since 2004 turned out to be topmost among all men’s cancers. PC etiology is poorly understood yet. Thus the role of human papillomaviruses (HPV) belonging to the highly oncogenic types is unclear while in some other human organs they were proven to be powerful carcinogens. Communications keep on emerging from various laboratories by authors who make mutually exclusive conclusions on the role of these viruses in PC genesis. It seems urgent to clarify the given problem from both theoretical and practical viewpoints. Firstly, this is the way to specify the origin of such a common cancer type as PC is. Secondly, if PC association with oncogenic HPV is confirmed the outlook for PC prevention is discovered by means of inoculating of boys with the vaccines designed for cervical cancer prevention. The present review of the literature contains analysis of data on possible HPV involvement in PC genesis.

предстательная железараквирусы папилломы человекаprostatecancerhuman papillomavirusesTorre L.A., Siegel R.L., Ward E.M., Jemal A. Global cancer incidence and mortality rates and trends - an update. Cancer Epidemiol Biomarkers Prev 2016;25(1):16-27. DOI: 10.1158/1055-9965. EPI-15-0578.Имянитов Е.Н. Эпидемиология и биология рака простаты. Практическая онкология 2008;9(2):57-64.Schröder F.H., Roobol M.J. Prostate cancer epidemic in sight? Eur Urol 2012;61(6):1093-5. DOI: 10.1016/j. eururo. 2012.03.019.Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИИОИ им. П.А. Герцена. 250 с.Заридзе Д.Г. Профилактика рака. М.: ИМА-Пресс, 2009. 222 с.zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical ap plication. Nat Rev Cancer 2002;2 (5):342-50. DOI: 10.1038/nrc798.zur Hausen H. To vaccination and beyond. Biochemistry (Moscow) 2008;73 (5):498-503. PMID: 18605974.Hrbacek J., Urban M., Hamsikova E. et al. Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study. BMC Cancer 2011;3(11):53. DOI: 10.1186/1471-2407-11-53.IARC Monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses. Vol. 90. Lyon, 2007.IARC Monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part B. Biological agents. Vol. 100. Lyon, 2011. 502 p.Ruijter E., van de Kaa C., Miller G. et al. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 1999;20(1):22-45. DOI:10.1210/edrv. 20.1.0356.Zambrano A., Kalantari M., Simoneau A. et al. Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. The Prostate 2002;53(4):263-76. DOI:10.1002/pros. 10 157.Taylor M.L., Mainous A.G., Wells B.J. Prostate cancer and sexually transmitted diseases: a meta-analysis. Family Medicine 2005;37(7):506-12. PMID: 15 988 645.Kasiske B.L., Snyder J.J., Gilbertson D.T., Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004;4(6):905-13. DOI:10.1111/j. 1600-6143.2004.00 450. x.Grulich A.E., van Leeuwen M.T., Falster M.O., Vajdic C.M. Incidence 2'2017 том 16 I vol. 16 of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370(9581):59-67. DOI:10.1016/S0140-6736(07)61050-2.Collett D., Mumford L., Banner N.R. et al. Comparison of the incidence of malignancy in recipients of different types of organ: A UK Registry Audit. Am J Transplant 2010;10(8):1889-96. DOI: 10.1111/j. 1600-6143.2010.03181. x.Engels E.A., Pfeiffer R.M., Fraumeni J.F. Jr. et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011;306(17):1891 -901. DOI: 10.1001/jama. 2011.1592.Leiros G.J., Galliano S.R., Sember M.E. et al. Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urology 2005;24 (5):15. DOI:10.1186/1471-2490-5-15.Martinez-Fierro M.L., Leach R.J., Gomez-Guerra L.S. et al. Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer 2010;10(6):326. DOI: 10.1186/1471-2407-10-326.Deschoolmeester V., Van Marck V., Baay M. et al. Detection of HPV and the role of p16INK4A overexpression as a surrogate marker for the presence of functional HPV oncoprotein E7 in colorectal cancer. BMC Cancer 2010;10(4):117. DOI: 10.1186/1471-2407-10-117.Golovina D.A., Trofimova O.B., Ermilova V.D. et al. Complex of molecular genetic and immunohistochemical methods for detection of human papillomavirus in the bladder cancer epithelium. Bull Exp Biol Med 2014;157(1):70-3. DOI: 10.1007/s10 517-014-2494-0.Smelov V., Eklund C., Bzhalava D. et al. Expressed prostate secretions in the study of human papillomavirus epidemiology in the male. PLOS One 2013;8(6):625-30. DOI: 10/1371/journal. pone. 0 066 630.Singh N., Hussain S., Kakkar N. et al. Implication of high risk human papillomavirus HR-HPV infection in prostate cancer in Indian population - a pioneering case-control analysis. Sci Rep 2015;5 (1):7822. DOI: 10.1038/srep07 822.Yow M.A., Tabrizi S.N., Severi G. et al. Detection of infectious organisms in archival prostate cancer tissues. BMC Cancer 2014;14(8):579. DOI: 10.1186/1471-2407-14-579.Yow M.A., Tabrizi S.N., Severi G. et al. Characterization of microbial communi ties with aggressive prostate cancer tissues. Infect Agent Cancer 2017;12(1):4. DOI: 10.1186/s13027-016-0112-7.Pascale M., Pracella D., Barbazza R. et al. Is human papillomavirus associated with prostate cancer survival? Dis Markers 2013;35(6):607-13. DOI: 10.1155/2013/735 843.Faoro V., Barbazza R., Bonin S. et al. Detection of HPV E7 oncoviral protein in cervical lesions by a new antibody. Appl Immun Mol Morphol 2013;21(4):341-50. DOI: 10.1152/japplphysiol. 00236.2013.Montironi R., Mazzuccheli R., Scarpelli M. et al. Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int 2005;95(8):1146-52. DOI:10.1111/j1464-410X. 2005.05 540. x.Thompson I.M., Ankerst D.P., Chi C. et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98(8):529-34. DOI: 10.1093/jnci/djj131.Dillner J., Knekt P., Boman J. et al. Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. Int J Cancer 1998; 75(4):564-7. PMID: 9466657.Adami H.O., Kuper H., Andersson S.O. et al. Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case control study. Cancer Epidem Biomark Prev 2003;12(9):872-5. PMID: 14504197.Korodi Z., Dillner J., Jellum E. et al. Human papillomavirus 16, 18 and 33 infections and risk of prostate cancer: a Nordic nested case control study. Cancer Epidem Biomark Prev 2005; 14(12):2952-5. DOI: 10.1158/1055-9965.EPI-05-0602.Sitas F., Urban M., Stein L. et al. The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infect Agent Cancer 2007;2(3):6. DOI: 10.1186/1750-9378-2-6.Sutcliffe S., Viscidi R.P., Till C. et al. Human papillomavirus types 16, 18 and 31 serostatus and prostate cancer risk in the Prostate Cancer Trial. Cancer Epidem Biomark Prev 2010;19(2): 614-8. DOI: 10.1158/1055-9965. EPI-09-1080.Franco E.L., Villa L.L., Sobrinho J.P. et al. Epidemiology of acquisition and clearance of cervical human papilloma infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180 (5):1415-23. DOI:10.1086/315086.Zumbach K., Kisseljov F., Sacharova O. et al. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia. Int J Cancer 2000;85(3):313-8. PMID: 10652419.Gillison M.L., Shah K.V. Role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr 2003;31:57-65. PMID: 12807947.Weijerman P.C., König J.J., Wong S.T. et al. Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. Cancer Res 1994;54(21):5579-83. PMID: 7923200.Weijerman P.C., van Drunen E., König J.J. et al. Specific cytogenetic aberrations in two novel human prostatic cell lines immortalized by human papillomavirus type 18 DNA Cancer Genet Cytogenet 1997;99(2):108-15. PMID: 9398864.Weijerman P.C., Zhang Y., Shen J. et al. Expression of prostatic factors measured by reverse transcription polymerase chain reaction in human papillomavirus type 18 deoxyribonucleic acid immortalized prostate cell lines. Urology 1998;51(4):657-62. PMID: 9586625.Hartwig S., Syrjanen S., Dominiak-Felden G. et al. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe. BMC Cancer 2012;12(1):30. DOI: 10.1186/1471-2407-12-30.Reiter P.L., Pendergraft W.F., Brewer N.T. Meta-analysis of human papillomavirus infection concordance. Cancer Epidem Biomark Prev 2010; 19(11):2916-31. DOI: 10.1158/1055-9965.EPI-10-0576.de Lima Rocha M.G., Faria F.L., Goncalves L. et al. Prevalence of DNA-HPV in male sexual partners of HPV infected women and concordance of viral types in infected couples. PloS One 2012;7(7):40 988. DOI: 10.1371/journal. pone. 0040988.Yang L., Xie S., Feng X. et al. Worldwide prevalence of human papillomavirus and relative risk of prostate cancer: a meta-analysis. Sci Rep 2015;5(10):14667. DOI: 10.1038/srep14667.